Figure 5.

LINC00941 enhances the glycolysis of PDAC cells via the Hippo pathway

(A) Luciferase report assays of pathways that reported involvement in cancer cell glycolysis. (B) qPCR results of Hippo pathway target genes upon LINC00941 knockdown. (C) Immunofluorescence staining of Yes1 associated transcriptional regulator (YAP1) in control and LINC00941 knockdown of PANC-1 cells. (D) Statistical results of YAP1 immunofluorescence staining. (E) Immunoblots of the Hippo pathway in control and LINC00941 knockdown PDAC cells. (F and G) Cell viability assay of PDAC cells transfected with mutant YAP1 (F) and LINC00941 plus verteporfin treatment. (H) ECAR assay of PDAC cells transfected with mutant YAP1. (I) qPCR results of glycolysis-altered genes in PDAC cells transfected with mutant YAP1. (J) ChIP-PCR results of YAP1 in PANC-1 cells. All statistical significances were calculated using two-tailed Student’s t tests to compare with the NC or control group. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.